Delray Medical Center Becomes First Hospital in Florida to Use New Technology for Stroke Patients

Delray Medical Center is the first hospital in the state of Florida to use the RED 62™ Reperfusion Catheter & BENCHMARK BMX96™ for stroke patients.  Neurointerventionalist, Dr. Dennys Reyes, is the first doctor in the county to use this technology.

The RED 62™ is designed to navigate complex distal vessel anatomy and deliver powerful aspiration along with the BENCHMARK BMX96™ to remove blood clots in acute ischemic stroke patients with large vessel occlusions. In addition, it provides faster navigation and shorter times to recanalize “brain vessels”.

“The RED 62™ is engineered with some of the latest innovations in tracking and aspiration technology to address large vessel blockages from a stroke located in more challenging areas, while maximizing powerful aspiration to remove blood clots,” said Dr. Reyes.  “With the help of the BENCHMARK BMX96™ Access System, hypotube technology provides a higher stability for more complex cases when it comes to treatment of a stroke.  In addition, when performing a procedure, the catheter is designed to increase versatility and visualization designed to help offer patients the best possible outcomes.”

As a comprehensive stroke center, Delray Medical Center has advanced technology and services to help with any neurological issues.  Our hospital is a member of the Advanced Neuroscience Network, and integrated delivery system of medical professionals and hospitals focused on offering a full continuum of neurological care throughout South Florida.

“This new technology gives patients who come to our hospital for stroke care the latest in neurologic care,” said Maggie Gill, chief executive officer of the Palm Beach Health Network & Delray Medical Center.  “This hospital continues to be at the forefront when it comes to the newest medical care in our community, and the RED 62™ Reperfusion Catheter & BENCHMARK BMX96™ is no exception.”

For more information about our neurosciences program, go to www.delraymedicalctr.com or call 561-498-4440.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”